Skip to main content

Scientists nix Alzheimer’s-causing brain plaques in mice. Could humans be next?

Alzheimer’s disease is the most common form of dementia, affecting roughly 5.7 million Americans at this moment. In 2018, Alzheimer’s and other dementias will cost the U.S. an estimated $277 billion — not to mention the immeasurable amount of emotion labor it inflicts on patients and their careers. Unfortunately, right now it is an incurable disease for those affected by it. While that will remain true for the time being, a promising new piece of research suggests that there may soon be a way to better treat or even prevent the disease altogether. In experiments with mice, researchers at Washington University School of Medicine have demonstrated that it is possible to remove the plaques which begin forming in the brains of future Alzheimer’s patients, sometimes years before the disease manifests.

These sticky masses are called amyloid plaques. As they form in the brain, they damage nearby cells. The plaques are made up of a brain protein called amyloid beta, along with another Alzheimer’s protein called Apolipoprotein E (ApoE). In their study, the Washington University researchers demonstrated that a DNA-based compound can be made to target ApoE in a way that also removes the plaques. It does this without removing the ApoE protein which is present in our blood and brain.

The DNA-based compound is an antibody called HAE-4. It was given to the mice in the study for six weeks and was found to cut the level of plaques in half. It could represent a new treatment for Alzheimer’s, without the side effects of some current alternatives.

“It is possible that what we have shown in mice with anti-ApoE antibodies in the future could move into human trials,” Dr. David Holtzman, head of the Department of Neurology, told Digital Trends. “Part of this will have to do with whether the effects we have seen in mice is similar to what is seen with anti-amyloid beta antibodies, but yet has less side effects. That remains to be determined.”

While it’s still far too soon to start celebrating the idea of a medicine people could proactively take to delay or stop the onset of Alzheimer’s, this still represents incredibly exciting research. Let’s hope that the subsequent steps prove as promising as the initial developments.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Space radiation can damage mice’s brains and cause anxiety, study shows
space radiation brain damage spaceradschool01 011 1

The Earth is protected from space radiation by its magnetosphere. NASA / SOHO

Out in the depths of space, far from the protection of Earth's atmosphere, radiation lurks. Space radiation is known to cause sickness and increase the lifetime risk of cancer in astronauts, and now scientists have published a study showing that exposure to space-like radiation can cause damage to the brains of mice and affect their behavior.

Read more
Elon Musk’s Neuralink wants to start operating on human brains next year
elon musks neuralink wants to start operating on human brains next year musk 2019

Proving that his brain can still generate grand ideas, the man responsible for Tesla, SpaceX, and the Boring Company took to a San Francisco stage on Tuesday evening, July 16, to shed some light on Neuralink, an outfit launched by Elon Musk in 2016 aimed at developing “ultra-high bandwidth brain-machine interfaces to connect humans and computers.”

The billionaire entrepreneur had, until now, revealed little about Neuralink, but at the special event, he said its main goals were to understand and treat brain disorders, and also to "preserve and enhance your own brain" to keep pace with artificial intelligence (A.I.).

Read more
Startup wants to reverse Parkinson’s and Alzheimer’s using human blood extract
alkahest parkinsons alzheimers trial elderly parkinson s patient

A cutting-edge startup is working on a treatment for neurodegenerative diseases such as Parkinson’s and Alzheimer’s by altering the concentration of plasma proteins in patients. This work is based on previous research from Stanford University indicating that cognitive decline in mice can be reversed through injections of blood taken from younger mice.

“Alkahest recently announced the initiation of a Phase 2 trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson’s disease with associated mild cognitive impairment or dementia,” Steven Braithwaite, Chief Scientific Officer at Alkahest, told Digital Trends. “As humans age, there is change in the makeup of the proteins in plasma. Some of the key, function-driving plasma proteins increase or decrease with time. At Alkahest, we have termed these changing proteins ‘chronokines.’”

Read more